{
    "paper_id": "ea3a6005c7d285432c3d5103ada9453d9aa75331",
    "metadata": {
        "title": "Analytical and Clinical Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection 1 2 Running title: Comparison of Three SARS-CoV-2 NAATs 3 4",
        "authors": [
            {
                "first": "Elizabeth",
                "middle": [],
                "last": "Smith",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Northwell Health Laboratories",
                    "location": {
                        "settlement": "Lake Success",
                        "region": "NY"
                    }
                },
                "email": ""
            },
            {
                "first": "Wei",
                "middle": [],
                "last": "Zhen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Northwell Health Laboratories",
                    "location": {
                        "settlement": "Lake Success",
                        "region": "NY"
                    }
                },
                "email": ""
            },
            {
                "first": "Ryhana",
                "middle": [],
                "last": "Manji",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Northwell Health Laboratories",
                    "location": {
                        "settlement": "Lake Success",
                        "region": "NY"
                    }
                },
                "email": ""
            },
            {
                "first": "Deborah",
                "middle": [],
                "last": "Schron",
                "suffix": "",
                "affiliation": {
                    "laboratory": "The Donald and Barbara Zucker School",
                    "institution": "Northwell Health Laboratories",
                    "location": {
                        "addrLine": "450 12 Lakeville Rd",
                        "postCode": "11042 13 14",
                        "settlement": "Lake Success",
                        "region": "NY"
                    }
                },
                "email": ""
            },
            {
                "first": "Scott",
                "middle": [],
                "last": "Duong",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Northwell Health Laboratories",
                    "location": {
                        "settlement": "Lake Success",
                        "region": "NY"
                    }
                },
                "email": ""
            },
            {
                "first": "Gregory",
                "middle": [
                    "J"
                ],
                "last": "Berry",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Northwell Health Laboratories",
                    "location": {
                        "settlement": "Lake Success",
                        "region": "NY"
                    }
                },
                "email": "gberry1@northwell.edu"
            }
        ]
    },
    "abstract": [
        {
            "text": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first identified in December 17 2019 and has quickly become a worldwide pandemic. In response, many diagnostic manufacturers have 18 developed molecular assays for SARS-CoV-2 under the Food and Drug Administration (FDA) Emergency 19",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Use Authorization (EUA) pathway. This study compared three of these assays: the Hologic Panther Fusion 20 SARS-CoV-2 assay (Fusion), the Hologic Aptima SARS-CoV-2 assay (Aptima) and the BioFire Diagnostics 21 COVID-19 test (BioFire), to determine analytical and clinical performance, as well as workflow. All three 22",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "assays showed a similar limit of detection (LOD) using inactivated virus, with 100% detection ranging from 23 500-1,000 genome equivalents/ml, whereas use of a quantified RNA transcript standard showed the same 24 trend, but had values ranging from 62.5 to 125 copies/ml, confirming variability in absolute quantification 25 of reference standards. The clinical correlation found that the Fusion and BioFire assays had a positive 26 percent agreement (PPA) of 98.7%, followed by the Aptima assay at 94.7% when compared to the 27 consensus result. All three assays exhibited 100% negative percent agreement (NPA). Analysis of 28 discordant results revealed that all four samples missed by the Aptima assay had Ct values >37 on the 29 Fusion assay. 30",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "In conclusion, while all three assays showed similar relative LODs, we showed differences in 31 absolute LODs depending on which standard was employed. In addition, the Fusion and BioFire assays 32 showed better clinical performance, while the Aptima assay showed a modest decrease in overall PPA. 33",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "These findings should be kept in mind when making platform testing decisions. 34",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Specimen collection and storage. Nasopharyngeal (NP) swabs were obtained from patients with clinical 74 signs/symptoms of COVID-19. Each collection used a sterile swab made from Dacron, rayon or nylon which 75 was placed into sterile 3 ml universal transport medium (UTM-various manufacturers) after collection. 76",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Samples were then transported at room temperature and were stored at 2-8\u2070C for up to 72 hours and 77 tested as soon as possible after collection. For the retrospective sample set, after routine patient testing, 78 aliquots of samples were taken and stored at -80\u2070C until testing of the three comparator NAATs could 79 occur. 80 81",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Samples were selected from specimens received for routine SARS-CoV-2 testing between April and May 83 of 2020. The selection included symptomatic patients of all genders and ages. A total of 150 84 nasopharyngeal (NP) samples (75 negative and 75 positive) were used for this study: 101 retrospective 85 specimens (51 negative, 50 positive) and 49 prospective, fresh specimens (24 negative, 25 positive). 86",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study design 82"
        },
        {
            "text": "Specimens were selected to represent our laboratory's positivity rate at the time this study was designed 87 (50 -60% at beginning of April 2020) and also included positive specimens spanning the range of positivity, 88 including those with low viral loads (characterized by high cycle threshold (Ct) values obtained by results 89 from initial clinical testing). The 101 retrospective specimens were initially tested per routine patient care 90 and then immediately aliquoted and frozen at -80\u2070C, remaining frozen until this study was performed. 91",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study design 82"
        },
        {
            "text": "Retrospective sample aliquots were thawed and immediately tested on the Fusion, Aptima, and BioFire 92 systems. Testing for prospective samples was performed within 48 hours of collection. Prospective 93 samples were run on the Fusion, Aptima and BioFire using the original UTM sample and aliquoted directly 94 into Hologic Lysis tubes and into BioFire Sample Injection Vial. This work was conducted as a quality 95 6 Hologic Panther Fusion\u00ae SARS-CoV-2 assay (Fusion). The Fusion assay (Hologic, Inc., San Diego, CA) was 98 performed on the Panther Fusion instrument according to the manufacturer's instructions for use. This 99 assay targets two unique regions of the ORF1ab section of the SARS-CoV-2 viral genome. A 500 \u00b5L aliquot 100 of the primary NP swab specimen is transferred into a Specimen Lysis Tube containing 710 \u00b5L lysis buffer 101 and is then loaded onto the Panther Fusion instrument. From this tube, the instrument removes 360 \u00b5l 102 for extraction. Each specimen is processed with an internal control (IC), which is added via the working 103",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study design 82"
        },
        {
            "text": "Panther Fusion Capture Reagent-S. Nucleic acid is purified using capture oligonucleotides and a magnetic 104 field, eluted in 50 \u00b5l, and 5 \u00b5l of the eluted nucleic acid is added to a Panther Fusion reaction tube. The 105 Each specimen is processed with an IC, which is added via the working Target Capture Reagent. Nucleic 119 acid is purified using capture oligonucleotides and a magnetic field, and the purified nucleic acid used as 7 template for the TMA reaction. After amplification, chemiluminescent probes hybridize to amplicons and 121 emit light measured by a luminometer in relative light units (RLUs). The IC signal and SARS-CoV-2-specific 122 signal are differentiated by kinetic profiles of the labeled probes (rapid vs slow). Assay results are 123 determined by a cut-off based on the total RLU and the kinetic curve type. Table 1 ) for testing across the different platforms. The same process was 145 followed for the Exact Diagnostics control, which had starting concentration of 200,000 copies/ml and 146 was diluted to make the same concentration of serial dilutions as those performed for the BEI material. 147 LOD was defined as the lowest dilution at which all replicates were positive (100% detection rate). 148 149 Workflow Evaluation. Workflow was evaluated using a calibrated timer to measure the time needed for 150 each step being evaluated, including hands-on time (HoT), assay run time and total turnaround time (TAT). 151",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 837,
                    "end": 844,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "Study design 82"
        },
        {
            "text": "HoT, assay run time, and TAT were calculated using the throughput of samples per run. algorithm per the instructions for use for each assay. Using these criteria, the LOD using inactivated SARS-170 CoV-2 virus was 1,000 GE/ml for the Fusion assay, 500 GE/ml for the Aptima assay, and 500 GE/ml for the 171 BioFire test ( Table 1 ). In addition, the LOD as determined using the Exact Diagnostics synthetic RNA 172 transcript was 62.5 copies/ml for both the Fusion and Aptima and 125 copies/ml for the BioFire. buffer mixing, addition of sample/buffer to the pouch, and loading onto the instrument. These additional 207 step for BioFire account for the increased HoT per specimen as seen in Table 4 . 208",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 321,
                    "end": 328,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 689,
                    "end": 696,
                    "text": "Table 4",
                    "ref_id": null
                }
            ],
            "section": "Study design 82"
        },
        {
            "text": "The present study compared the analytical sensitivity (LOD), clinical performance, and workflow 210 of three SARS-CoV-2 NAATs in 150 NP swab specimens. Our two independent LOD analyses revealed that 211 while all 3 assays had an LOD that was within 1 dilution factor of each other within a given control material, 212 absolute LODs with quantified inactivated virus (500-1,000 GE/ml) were several-fold higher than the 213 value obtained when using quantified synthetic RNA (62.5-125 copies/ml). This difference in absolute 214 LOD values reflects the inherent difficulty in comparing standards that have been prepared and 215 quantitated differently and have very high stock concentrations requiring significant dilutions for LOD 216 panel testing (i.e., any quantification error and/or pipetting error of the stock will be magnified in a 217 dilution series). Of interest, the LOD calculations for BioFire using the synthetic RNA standard only showed 218 amplification in two of three gene targets, since ORF1ab is included in the Exact diagnostics control, but 219 ORF 8 is not included. Considering this discrepancy, the decreased LOD relative to the Fusion and Aptima 220 when using the quantified synthetic RNA is likely due to the lack of ORF 8 target material. (GSD-3, 4, 6, and 48) had Ct values ranging from 230 37.3-40.5, suggesting that the Aptima assay is slightly less sensitive than the Fusion and Biofire assays. Of and resulted as positive as per the EUA IFU, suggesting that these were also weak positives on the BioFire 233 assay. 234",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 1268,
                    "end": 1289,
                    "text": "(GSD-3, 4, 6, and 48)",
                    "ref_id": null
                }
            ],
            "section": "Discussion 209"
        },
        {
            "text": "Workflow comparisons between the Fusion and the Aptima were quite similar, both being optimal 235 in high-volume testing situations (> 1,000 tests/24 hours), whereas the BioFire assay had an advantage of 236",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "fast sample to answer time, allowing for faster detection and diagnosis that is useful in urgent situations. 237",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "Other comparator studies of the Fusion assay have recently been reported, including: a study 238 comparing Fusion to the modified CDC assay, GenMark ePlex, DiaSorin Simplexa (6); a study comparing 239",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "Cepheid, ID NOW, and GenMark using Fusion as the reference standard (7); a study comparing Fusion, 240",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "Cepheid, DiaSorin, cobas, and a laboratory-developed test (LDT) (8) ; and a study comparing Fusion to an 241 in-house LDT targeting the envelope gene (9). In general, these reports show that the Fusion SARS-CoV-2 242 assay is comparable, if not superior, to other molecular platforms available for SARS-CoV-2 testing. In 243 particular, these evaluations showed that Fusion, DiaSorin and Cepheid tended to have better analytical 244 sensitivity and fewer false negatives in clinical testing than other assays. The low rate of false negatives is 245 a critical performance aspect, as missed positive results allow for further spread of the disease and 246 potential patient mismanagement. These comparison studies, while not clinical trials as would be typical 247 of new FDA-cleared IVD assays, have provided a window into the relative real world clinical performance 248 characteristics of these assays, which has been a significant knowledge gap since these SARS-CoV-2 EUA 249 molecular assays first became available. Among these knowledge gaps are relative performance data for 250 the Aptima and BioFire tests. To our knowledge, this is the first report comparing both the Aptima and 251",
            "cite_spans": [
                {
                    "start": 64,
                    "end": 67,
                    "text": "(8)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "BioFire assay to any other NAAT for SARS-CoV-2 detection. 252",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "It is worth noting that the LOD for the Fusion SARS-CoV-2 assay as determined in this study was 253 1,000 GE/ml when using inactivated virus, while the LOD determined in a previous study by our laboratory 254 was 83 \u00b136 copies/ml (6) and an additional LOD study performed as part of this study once again using 255 the same synthetic quantified RNA standard also previously published showed a comparable LOD of 62.5 256 LOD values when using different standards, specifically inactivated virus vs. synthetic RNA standards. 258",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "This study does have limitations, being a single site study with a limited number of NP swab 259 specimens (n = 150) included in the clinical evaluation. However, this specimen set was selected to be 260 representative of our patient population (including samples from patients of all ages and both genders) 261 and positivity rate (50-60% in the beginning of April 2020), and included samples with a range of viral 262 loads (low, moderate, high). Some initial equivocal or invalid results (n=3) by BioFire and Fusion required 263",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "retesting, but only 1 remained unresolved on retest and was removed from the agreement analysis for 264 the Fusion assay. 265",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "In conclusion, our data show that the Fusion, Aptima and BioFire SARS-CoV-2 NAATs exhibit 266 similar LODs, even when tested using two different quantified standards. In addition, the Fusion and 267 125 copies/ml GE, genomic equivalents; LOD, limit of detection 313 a. The LOD by positivity rate for each NAAT is highlighted in bold. 314 b. Numbers of replicates at each dilution that gave initial equivocal results and required repeat testing: 0 315",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "(1,000 GE/ml), 1 (500 GE/ml), 1 (250 GE/ml), 5 (125 GE/ml), 2 (62.5 GE/ml), 0 (31.3 GE/ml). 316 c. Numbers of replicates at each dilution that gave initial equivocal results and required repeat testing: 0 317",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        },
        {
            "text": "(1,000 copies/ml, 500 copies /ml and 250 copies /ml), 2 (125 copies /ml), 6 (62.5 copies /ml), 4 (31.3 318 copies/ml). 319 ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion 209"
        }
    ],
    "bib_entries": {
        "BIBREF3": {
            "ref_id": "b3",
            "title": "First Case of 2019 Novel Coronavirus in the United States",
            "authors": [],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "279",
            "issn": "10",
            "pages": "929--936",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2001191"
                ]
            }
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Centers for Disease Control and Prevention Web site",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering at Johns",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Coronavirus Disease 2019-(COVID-19) People Who",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Are at Higher Risk for Severe Illness",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Report of the WHO-China Joint Mission on Coronavirus Disease",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Comparison of Four Molecular In Vitro Diagnostic Assays for",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Zhen",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Manji",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Smith",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "J"
                    ],
                    "last": "Berry",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Platforms for the Detection of SARS-CoV-2",
            "authors": [],
            "year": 2020,
            "venue": "JCM online",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1128/JCM.00783-299"
                ]
            }
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Commercially Available and Laboratory Developed Assays for in vitro Detection of SARS-CoV-2 in",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "The measurement of observer agreement for categorical data",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Landis",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "G"
                    ],
                    "last": "Koch",
                    "suffix": ""
                }
            ],
            "year": 1977,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Interrater reliability: the kappa statistic",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Mchugh",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Biochem Med (Zagreb)",
            "volume": "22",
            "issn": "3",
            "pages": "276--310",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Fusion assay amplifies and detects two conserved regions of the ORF1ab section of the SARS-CoV-2 viral 106 genome. Both amplicons are detected by probes using the same fluorescent reporter, with amplification 107 of either or both regions contributing to a single fluorescent signal and single Ct value. Reporting of a 108 positive specimen requires only one of the two targets to be detected (ORF1ab region 1 Aptima SARS-CoV-2 assay (Aptima). The Aptima assay (Hologic, Inc., San Diego, CA) is a NAAT 112 that uses target capture and transcription-mediated amplification (TMA) technologies for the isolation 113 and amplification of SARS-CoV-2 RNA. This assay targets two unique regions of the ORF1ab section of the 114 SARS-CoV-2 viral genome and is performed on the Panther instrument. All testing was performed 115 according to the manufacturer's instructions and is briefly described. A 500 \u00b5L aliquot of the primary NP 116 swab specimen is transferred into a Specimen Lysis Tube containing 710 \u00b5L lysis buffer and this tube is 117 then loaded on to the Panther instrument. From the Specimen Lysis Tube, 360 \u00b5l is taken for each reaction.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "118",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "COVID-19 Test (BioFire). The BioFire COVID-19 Test (Salt Lake City, UT) was performed on the 126 BioFire FilmArray 12 Bay Torch System as per the manufacturer's instructions. This assay targets two 127 unique regions of the ORF1ab section and one unique region of the ORF8 section of the SARS-CoV-2 viral 128 genome. The test pouch (1 per sample to be tested) is prepared by injecting Hydration Solution into the 129 pouch hydration port. Approximately 300 \u00b5l of sample is added with a provided transfer pipette to the 130 Sample Injection Vial, followed by the addition of a single-use Sample Buffer Tube to the Sample Injection 131 Vial and inverted to mix. The sample mix is injected into the pouch sample port. Within the pouch, the 132 sample is lysed by agitation (bead beating), and all nucleic acid is extracted and purified using magnetic 133 bead technology. Nested multiplex PCR is performed and endpoint melting curve data is used to detect 134 and generate a result for each target assay on the BioFire COVID-19 Test. 135 136 Analytical Sensitivity. Limit of detection (LOD) was performed using quantified inactivated (gamma-137 irradiated) SARS-CoV-2 material from Isolate USA-WA1/2020 (NR-52287, BEI Resources, Manassas, VA) 138 and SARS-CoV-2 synthetic RNA quantified control containing five gene targets (E, N, ORF1ab, RdRP and S 139 Genes of SARS-CoV-2) from Exact Diagnostics (SKU COV019, Fort Worth, TX). The BEI material was 140 provided at 4.1 x 10^9 genome equivalents (GE)/ml (2.8 x 10^5 TCID50/ml pre-inactivation of virus) 141 concentration, from which the following serial dilutions were prepared (in GE/ml): 1,000, 500, 250, 125, 142 62.5, 31.3. Dilutions were prepared using Ambion\u00ae RNA Storage Solution (Catalog No.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Statistical methods. The consensus result was based on the majority results of the 3 NAATs (Fusion, 154 Aptima, BioFire) and was defined as follows: consensus positive = positive result in \u22652 of 3 NAATs; 155 consensus negative = negative result in \u22652 of 3 NAATs. The final result of each NAAT was based on each 156 manufacturer's results interpretation algorithm. Percent positive agreement (PPA), percent negative 157 agreement (NPA), positivity rate, Kappa, and two-sided (upper/lower) 95% confidence interval (CI) were 158 calculated using Microsoft\u00ae Office Excel 365 MSO software (Microsoft, Redmond, WA). As a measure of 159 overall agreement, Cohen's kappa values (\u03ba) were calculated, with values categorized as follows: >0.inactivated SARS-CoV-2 virus (BEI Resources) and Exact Diagnostics SARS-CoV-2 166 synthetic RNA quantified control were used to prepare serial dilution panels (1,000 to 31.3 [GE or 167 copies]/ml, in 2-fold dilutions) to determine the LOD of each assay. The LOD was defined as the lowest 168 dilution in which all replicates were detected (100% positivity rate), using the results interpretation 169",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "of the 150 clinical specimens on all 3 platforms, consensus results were determined 176 for each sample (consensus positive = positive result in \u22652 of 3 NAATs; consensus negative = negative 177 result in \u22652 of 3 NAATs) and results from each NAAT were compared to the consensus result. The Fusion 178 and BioFire tests exhibited the highest positive percent agreement (PPA) of 98.7%, while the Aptima assay 179 had a PPA of 94.7% (Table 2). NPAs were 100% for all three NAATs, with no false positive results for any 180 platform. Cohen's kappa values were 0.987, 0.947, and 0.987 for the Fusion, Aptima and BioFire tests, 181 respectively, all of which indicate an \"almost perfect\" level of agreement with the consensus result. 182 Initial equivocal or invalid results occurred for 3 samples out of the sample set: 2 equivocal results 183 for the BioFire test and 1 invalid result for the Fusion assay. The initial BioFire results for the 2 samples 184 were one of three targets detected (one of the ORF1ab targets); repeat testing gave the same result for 185 both samples, for an overall interpretation of \"detected\" as per the manufacturer. The initial Fusion 186 invalid result repeated as invalid and this sample was removed from the overall agreement analysis for 187 the Fusion assay; as this sample was negative by both Aptima and BioFire giving a consensus negative 188 result, this sample was kept in the overall agreement analyses for Aptima and BioFire. 189 There were no discordant results among the prospective, fresh sample set; all of the discordant 190 samples occurred among the retrospective sample set. Of the three NAATs evaluated, the Aptima assay 191 had the most discordant results with the consensus (n=4), followed by the Fusion and BioFire tests each 192 with one discordant result. Discordant sample results are shown in Table 3. The four discordant samples 193 for Aptima had Fusion Ct values \u226537.3, indicating lower viral titers in these samples. The discordant BioFire 194 sample had a Fusion Ct value of 35.7. For the 5 Fusion/Aptima discordant samples, the BioFire COVID-19 195 Test detected only 2 of 3 targets in each sample (GSD-3, GSD-6, GSD-23) or detected 1 of 3 targets in each 196 sample twice for an overall result of detected (GSD-4, GSD-48) (Table 3). 197 198 Workflow. 199 Workflow parameters along with basic assay characteristics are presented in Table 4. Maximum 200 sample throughput in 8 hour and 24 hour time periods were considerably higher on the Fusion and Aptima 201 platforms (Panther Fusion: 335/8 hours and 1150/24 hours; Panther Aptima: 275/8 hour and 1020/24 202 hours), while throughput for BioFire was 72/ 8 hour and 216/ 24 hours. Hands on time (HoT) per specimen 203 for the both Fusion and Aptima assays are 1 minute, where the BioFire HoT is 3 minutes per specimen. 204 Sample preparation for the Fusion and Aptima assays consist of aliquoting 500 \u00b5L of sample into a lysis 205 tube. Sample preparation for the BioFire consists of five steps including pouch hydration, sample and 206",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "that the Fusion and Biofire had similar PPA (98.7%), while the Aptima showed a slight 222 decrease at 94.7% PPA due to 4 false negative results among samples in the frozen retrospective set. 223 Cohen's kappa values showed almost perfect agreement (range: 0.947 -0.987) between each assay and 224 the consensus result. NPAs were 100% for all NAATs, suggesting each of these assays has high specificity. 225 All discordant results were false negatives as compared to the consensus result, with Fusion and 226 BioFire each demonstrating one missed positive and Aptima demonstrating four missed positives. A closer 227 analysis of discordant results showed that the sample missed by the Fusion (GSD-23) only had two gene 228 targets detected by BioFire (2a/2e) and the sample missed by the BioFire (GSD-7) had a Ct value of 35.7 229 on the Fusion. All four samples missed by the Aptima",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "BioFire assays have comparable clinical performance for detection of SARS-CoV-2 in NP swabs, with a PPA 268 of 98.7%, while the Aptima assay showed a slight reduction at 94.7% PPA. All 3 assays demonstrated 100% 269 NPA, suggesting high specificity. These performance characteristics, as well as testing volume and 270 workflow requirements, should be considered when making testing platform decisions. 271 Gregory Berry has previously given education seminars for Hologic, Inc. and BioFire Diagnostics and has 273 received Honorariums. 274 Summary of Limit of Detection results. 312",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Clinical performance comparison of three SARS-CoV-2 NAATs in NP swab specimens (n = 150). 320 321 a. \u00b1, upper/lower 95% 322 b. CI, confidence interval 323 c. One sample gave an invalid result and was excluded from the Fusion agreement analysis. 324",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Details of discordant samples. 325 Individual SARS-CoV-2 NAAT results a SAMPLE ID",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}